BioSpace News Archive

As previously disclosed, the US authority FDA has approved SpectraCure’s new and revised study protocol for the clinical study on patients with recurrent prostate cancer.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview at the Virtual Life Sciences Investor Forum on Thursday, June 25, 2020, at 10 a.m. EDT.

Jupiter Medical Center – ranked number one for safety, quality and patient satisfaction in Palm Beach County and the Treasure Coast region – is the only hospital in the area to deploy an array of state-of-the-art technology solutions to ensure patients returning for elective procedures receive care in the safest possible healthcare environment.

June 18, 2020 12:00 UTC - Advancing medicines to transform the lives of patients with life-limiting diseases of the nervous system SAN DIEGO--( BUSINESS WIRE )-- Engrail Therapeutics™ (Engrail) (the Company) today announced the close of a $32 million Series A financing round. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led the round. The Company plans to use the proceeds from the financing to support the clinical development of its f

Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60 million in an upfront cash payment; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones

XP-3924 resulted in a 62% reduction of hyperglycemia after a glucose challenge XP-3924 showed improved glucose control when compared to Humulin® R alone XP-3924 showed promising glucose control when compared to both Humulin® R and co-administered injections of Humulin® R and Symlin® XP-3924 was observed to be safe and well tolerated in this study CHICAGO--( BUSINESS WIRE )-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty

Pear Therapeutics Announces Market Authorization of reSET ® from the Health Science Authority in Singapore for the Treatment of Adults with Substance Use Disorder HSA’s positive decision marks Pear’s first regulatory authorization outside of U.S. reSET is the first HSA-authorized prescription digital therapeutic to be available in Singapore BOSTON & SAN FRANCISCO--( BUSINESS WIRE )-- Pear Therapeutics, Inc. today announced that the

Companies Aim to Produce 10,000 Puritan Bennett™ 560 Ventilators Together in the United States Over the Next Year Partnership Established after Medtronic Announces Ventilator Open Source Initiative DUBLIN and MOUNT PLEASANT, Wis., June 18, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) and Foxconn Industrial Internet, a business group within Foxconn Technology Group (Foxconn), announced today that Foxconn has successfully completed Medtronic’s regulatory and quality requirements nec

Aegea Biotechnologies, Inc. (“Aegea”) ( www.aegeabiotech.com ) , a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces progress on the development of two COVID-19 d

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRA TM , the company’s immunotherapy product candidate. Upon issuance, the new patent will provide additional intellectual property protection around methods of using ALLOCETRA TM and pharmaceutical compositions comprising the same. The company expec